Modified GRF (1-29) 2mg (aka CJC-1295 w/o DAC)
€12.95
- Description
- Benefits
- Risks
- Additional information
- Research
Description
Modified GRF 1-29 (also known as CJC-1295 without DAC) is a synthetic analogue of growth hormone-releasing hormone (GHRH), studied in laboratory environments for its role in growth hormone (GH) pulsatile release, endocrine signalling, and short-acting peptide dynamics.
Unlike CJC-1295 with DAC, this modified version is designed for shorter activity duration, making it particularly useful in research models that aim to replicate natural GH pulsatility and physiological hormone release patterns.
In controlled laboratory settings, Modified GRF 1-29 interacts with GHRH receptors in the pituitary gland, stimulating growth hormone secretion in a controlled and time-dependent manner.
Across Ireland and Europe, this peptide is commonly studied in areas including:
- Growth hormone pulsatility and regulation
- GHRH receptor activation and endocrine signalling
- GH/IGF-1 axis research
- Short-acting peptide pharmacokinetics
This product is supplied as a high-purity research peptide, intended strictly for scientific and laboratory use.
Disclaimer: This product is strictly for research purposes only and is not for human consumption.
Technical Information – Modified GRF 1-29
| Specification | Details |
|---|---|
| Product Name | Modified GRF 1-29 (CJC-1295 without DAC) |
| Compound Type | Synthetic GHRH analogue peptide |
| Functional Class | Growth hormone-releasing hormone analogue |
| Mechanism of Action | Activates GHRH receptors to stimulate GH release |
| Biological Targets | Pituitary gland, GH/IGF-1 axis |
| Activity Profile | Short-acting (no DAC modification) |
| Format | Lyophilised powder |
| Purity | Research-grade (high purity) |
| Storage | Refrigerated (2–8°C, protected from light) |
| Application | Laboratory research use only |
* Images for illustration purposes only
Further Refrences: PubChem Entry
Researched Benefits & Focus Areas – Modified GRF 1-29
1. Pulsatile Growth Hormone (GH) Release Research
Modified GRF 1-29 has been studied for:
- Stimulation of GH release in a pulsatile pattern
- Investigation of natural hormone secretion cycles
- Analysis of pituitary signalling behaviour
Reference basis: Derived from endocrinology research examining GHRH analogues and physiological GH release patterns.
2. GHRH Receptor Activation
Research has explored:
- Binding to growth hormone-releasing hormone receptors
- Activation of pituitary GH secretion pathways
- Interaction with endocrine signalling systems
Reference basis: Based on biochemical studies investigating GHRH receptor signalling and peptide-receptor interactions.
3. Short-Acting Peptide Dynamics
Modified GRF 1-29 is designed for:
- Short duration of activity in experimental models
- Better simulation of natural endocrine rhythms
- Research into controlled hormone release timing
Reference basis: Supported by pharmacokinetic studies comparing short-acting vs long-acting peptide analogues.
4. GH/IGF-1 Axis Research
- Studied for its role in growth hormone and IGF-1 interaction
- Explored in endocrine feedback loop models
- Investigated for hormonal regulation pathways
Reference basis: Derived from research into GH/IGF-1 axis regulation and endocrine system behaviour.
Disclaimer: These are research-based findings only. This product is not intended for human use or consumption.
Researched Risks & Considerations – Modified GRF 1-29
1. Hormonal System Influence
- May significantly affect growth hormone levels
- Potential for endocrine imbalance in research models
Reference basis: Based on studies examining GH regulation and hormonal feedback systems.
2. Short Duration of Action
- Requires frequent administration in experimental models
- May result in variable signalling depending on timing
Reference basis: Derived from research into short-acting peptide pharmacokinetics.
3. Endocrine Feedback Effects
- May influence natural hormonal feedback loops
- Potential for overstimulation or suppression of pathways
Reference basis: Based on studies examining GH/IGF-1 axis regulation and feedback mechanisms.
4. Limited Long-Term Research
- Lack of extensive long-term data
- Primarily studied in controlled laboratory environments
Reference basis: Reflects the current stage of GHRH analogue research.
Disclaimer: These risks are based on available research data only. This product is strictly a research peptide and not for human consumption.
Additional information
| Weight | 23 kg |
|---|---|
| Dimensions | 12 × 23 × 56 cm |
| Quantity | 1 Vial, 1 Kit (10 Vials) |
Related Products
FEATURED PRODUCTS
BEST SELLING PRODUCTS
LATEST PRODUCTS
TOP RATED PRODUCTS